Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Ozanimod is a novel oral small-molecule immunomodulator developed primarily for the treatment of relapsing forms of multiple sclerosis (RMS) and moderate to severe ulcerative colitis. Chemically, it functions as a selective sphingosine-1-phosphate (S1P) receptor modulator. Its molecular formula is C26H30N4O5, and its unique CAS registry number is 1897786-98-9. This compound was originally designed to target S1P receptors 1 and 5, which are critical in regulating lymphocyte trafficking. By binding to these receptors on lymphocytes, Ozanimod induces their internalization, effectively preventing them from exiting lymphoid tissues and migrating into the central nervous system or inflamed gastrointestinal mucosa. This mechanism significantly reduces the autoimmune attack that characterizes RMS and limits the chronic inflammation seen in ulcerative colitis.
Approved by regulatory agencies such as the U.S. FDA, Ozanimod represents a significant advancement in neurology and gastroenterology, offering an alternative to injectable therapies or those with more complex safety profiles. Clinical trials have demonstrated its efficacy in reducing annualized relapse rates in patients with RMS and inducing clinical remission in those suffering from ulcerative colitis. The drug is administered orally once daily, improving patient adherence compared to parenteral options. However, like all potent immunomodulators, it requires careful monitoring for potential side effects, including bradycardia, infections, and liver enzyme elevations. Patients must undergo specific cardiac assessments before initiation due to the risk of heart rate reduction. Furthermore, because it alters immune cell distribution, there is a theoretical concern regarding increased susceptibility to certain viral infections, necessitating vaccination updates prior to therapy.
The development of Ozanimod highlights the growing trend toward targeted oral biologics that balance efficacy with convenience. While it does not cure these chronic conditions, it provides a powerful tool for managing disease activity and preserving long-term quality of life. As research continues, ongoing studies are exploring its potential utility in other autoimmune disorders where S1P signaling plays a pivotal role. Overall, Ozanimod stands as a cornerstone in modern therapeutic strategies for immune-mediated inflammatory diseases, bridging the gap between high-efficacy interventions and patient-friendly administration routes.